LRRK2 and Parkinson disease: We also studied endogenous LRRK2 activity and phosphorylation in EBV-transformed lymphoblastoidcells derived from a Parkinson's disease patient harbouring a homozygous LRRK2(G2019S) mutation, incomparison with those derived from a second individual without an LRRK2 mutation, who presented withno disease (Figure 3).